AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization

Duhoux, F., Ibrahim, N., Papadamitriou, K., Canon, J.-L., Morales Murillo, S., Sanchez Rovira, P., Oliveira, M., Doger, B., Peguero, J., Marathe, O., & Triebel, F. (2023). AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization. ESMO Open, 8(1), 101443. https://doi.org/10.1016/j.esmoop.2023.101443 (Original work published 2023)